Physician profile
Alan S Yeo
NPI 1417983628
$1,029.30
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.11 · 2020: $170 · 2021: $267 · 2022: $311 · 2023: $107 · 2024: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $185.09 | 2020-2024 | Trintellix |
| Abbvie INC. | $161.96 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $153.97 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $148.56 | 2019-2022 | |
| Lundbeck LLC | $79.85 | 2022-2024 | Rexulti |
| Alkermes, INC. | $76.76 | 2021-2023 | Lybalvi |
| Vanda Pharmaceuticals INC. | $47.39 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $46.76 | 2021-2022 | |
| Harmony Biosciences LLC | $36.93 | 2022 | |
| Shire North American Group INC | $32.41 | 2019 | |
| Bausch Health US, LLC | $23.02 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.68 | 2020 | |
| Adlon Therapeutics L.P. | $14.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Yeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.